Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications

Overview

Journal Front Cell Neurosci

Specialty Cell Biology

Date 2017 Sep 29

PMID 28955204

Citations 8

Authors

Cristina Miguelez

Abdelhamid Benazzouz

Luisa Ugedo

Philippe De Deurwaerdere

Affiliations

Soon will be listed here.

Abstract

The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonergic (5-HT) system has been long established and has received increased attention during the last decade. Most studies have focused on the fact that L-DOPA can be transformed into dopamine (DA) and released from 5-HT terminals, which is especially important for the management of L-DOPA-induced dyskinesia. In patients, treatment using L-DOPA also impacts 5-HT neurotransmission; however, few studies have investigated the mechanisms of this effect. The purpose of this review is to summarize the electrophysiological and neurochemical data concerning the effects of L-DOPA on 5-HT cell function. This review will argue that L-DOPA disrupts the link between the electrical activity of 5-HT neurons and 5-HT release as well as that between 5-HT release and extracellular 5-HT levels. These effects are caused by the actions of L-DOPA and DA in 5-HT neurons, which affect 5-HT neurotransmission from the biosynthesis of 5-HT to the impairment of the 5-HT transporter. The interaction between L-DOPA and 5-HT transmission is especially relevant in those Parkinson's disease (PD) patients that suffer dyskinesia, comorbid anxiety or depression, since the efficacy of antidepressants or 5-HT compounds may be affected.

Citing Articles

Integration of Gut Microbiota, Serum Metabolomic, and Network Pharmacology to Reveal the Anti Insomnia Mechanism of Mongolian Medicine Sugemule-4 Decoction on Insomnia Model Rats.

Du L, Yang D, Wu L, Mei L, Wu S, Ba Y Drug Des Devel Ther. 2024; 18:2617-2639.

PMID: 38957410 PMC: 11217142. DOI: 10.2147/DDDT.S455600.

Levodopa Rescues Retinal Function in the Transgenic A53T Alpha-Synuclein Model of Parkinson's Disease.

Tran K, Wong V, Vessey K, Finkelstein D, Bui B, Nguyen C Biomedicines. 2024; 12(1).

PMID: 38255235 PMC: 10813165. DOI: 10.3390/biomedicines12010130.

Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.

Kaminska K, Lenda T, Konieczny J, Lorenc-Koci E Psychopharmacology (Berl). 2022; 239(11):3633-3656.

PMID: 36178508 PMC: 9584871. DOI: 10.1007/s00213-022-06238-x.

Sex Disparities in the Self-Evaluation of Subthalamic Deep Brain Stimulation Effects on Mood and Personality in Parkinson's Disease Patients.

Dietrich A, Koeppen J, Buhmann C, Potter-Nerger M, Pinnschmidt H, Oehlwein C Front Neurol. 2020; 11:776.

PMID: 32849228 PMC: 7412792. DOI: 10.3389/fneur.2020.00776.

6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata.

Vegas-Suarez S, Pisano C, Requejo C, Bengoetxea H, Lafuente J, Morari M Br J Pharmacol. 2020; 177(17):3957-3974.

PMID: 32464686 PMC: 7429490. DOI: 10.1111/bph.15145.

References

Miller D, Abercrombie E . Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem. 1999; 72(4):1516-22. DOI: 10.1046/j.1471-4159.1999.721516.x. View

Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M . Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport. 1999; 10(3):631-4. DOI: 10.1097/00001756-199902250-00034. View

Biggs C, Starr M . Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Synapse. 1999; 34(1):36-46. DOI: 10.1002/(SICI)1098-2396(199910)34:1<36::AID-SYN5>3.0.CO;2-G. View

Kannari K, Tanaka H, Maeda T, Tomiyama M, Suda T, Matsunaga M . Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J Neurochem. 2000; 74(1):263-9. DOI: 10.1046/j.1471-4159.2000.0740263.x. View

Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M . Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem. 2001; 76(5):1346-53. DOI: 10.1046/j.1471-4159.2001.00184.x. View

Yamato H, Kannari K, Shen H, Suda T, Matsunaga M . Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport. 2001; 12(6):1123-6. DOI: 10.1097/00001756-200105080-00015. View

Puig M, Celada P, Shapiro D, Roth B, Mengod G, Artigas F . Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. J Neurosci. 2001; 21(24):9856-66. PMC: 6763049. View

Lucas G, Debonnel G . 5-HT4 receptors exert a frequency-related facilitatory control on dorsal raphé nucleus 5-HT neuronal activity. Eur J Neurosci. 2002; 16(5):817-22. DOI: 10.1046/j.1460-9568.2002.02150.x. View

Lucas G, Compan V, Charnay Y, Neve R, Nestler E, Bockaert J . Frontocortical 5-HT4 receptors exert positive feedback on serotonergic activity: viral transfections, subacute and chronic treatments with 5-HT4 agonists. Biol Psychiatry. 2005; 57(8):918-25. DOI: 10.1016/j.biopsych.2004.12.023. View

10.

Scholtissen B, Verhey F, Steinbusch H, Leentjens A . Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm (Vienna). 2005; 113(1):59-73. DOI: 10.1007/s00702-005-0368-3. View

11.

Scholtissen B, Verhey F, Adam J, Weber W, Leentjens A . Challenging the serotonergic system in Parkinson disease patients: effects on cognition, mood, and motor performance. Clin Neuropharmacol. 2006; 29(5):276-85. DOI: 10.1097/01.WNF.0000229013.95927.C7. View

12.

Zhang Q, Gao R, Liu J, Liu Y, Wang S . Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model of Parkinson's disease. Sheng Li Xue Bao. 2007; 59(2):183-9. View

13.

Carta M, Carlsson T, Kirik D, Bjorklund A . Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007; 130(Pt 7):1819-33. DOI: 10.1093/brain/awm082. View

14.

Lucas G, Rymar V, Du J, Mnie-Filali O, Bisgaard C, Manta S . Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron. 2007; 55(5):712-25. DOI: 10.1016/j.neuron.2007.07.041. View

15.

Gudelsky G, Yamamoto B . Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacol Biochem Behav. 2007; 90(2):198-207. PMC: 2505334. DOI: 10.1016/j.pbb.2007.10.003. View

16.

Guiard B, El Mansari M, Merali Z, Blier P . Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol. 2008; 11(5):625-39. DOI: 10.1017/S1461145707008383. View

17.

Kaya A, Vlamings R, Tan S, Lim L, Magill P, Steinbusch H . Increased electrical and metabolic activity in the dorsal raphe nucleus of Parkinsonian rats. Brain Res. 2008; 1221:93-7. DOI: 10.1016/j.brainres.2008.05.019. View

18.

Carta M, Carlsson T, Munoz A, Kirik D, Bjorklund A . Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Prog Brain Res. 2008; 172:465-78. DOI: 10.1016/S0079-6123(08)00922-9. View

19.

Wang S, Zhang Q, Liu J, Wu Z, Wang T, Gui Z . Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat. Neuroscience. 2009; 159(2):850-61. DOI: 10.1016/j.neuroscience.2008.12.051. View

20.

Munoz A, Carlsson T, Tronci E, Kirik D, Bjorklund A, Carta M . Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol. 2009; 219(1):298-307. DOI: 10.1016/j.expneurol.2009.05.033. View